Healthcare Acquisition Corp. and PharmAthene Reconfirms Receipt of Stockholder Approval for Their Merger

  
    
  
  
    
      Healthcare Acquisition Corp. (AMEX:HAQ), a publicly-traded special 
      purpose acquisition company, and PharmAthene, Inc., a biodefense company 
      developing and commercializing medical countermeasures against 
      biological and chemical threats, today announced that the trading halt 
      in the stock and warrants of the Company was the result of inaccurate 
      information received after its stockholders meeting from its transfer 
      agent. The trading was halted while the parties and the transfer agent 
      for the Company investigated the accuracy of the previously reported 
      vote.
    
    
      About PharmAthene, Inc.
    
    
      PharmAthene was formed as a result of a merger with Healthcare 
      Acquisition Corp. PharmAthene is a biodefense company developing and 
      commercializing medical countermeasures against biological and chemical 
      threats. PharmAthene’s lead programs include 
      Valortim™ for the prevention and treatment of 
      anthrax infection and Protexia® for the 
      prevention and treatment of morbidity and mortality associated with 
      exposure to chemical nerve agents. For more information on PharmAthene, 
      please visit www.PharmAthene.com. 
      Healthcare Acquisition Corp. was a blank check company that was formed 
      for the specific purpose of consummating a business combination.
    
    
      Forward Looking Statement Disclosure
    
    
      This press release contains certain "forward-looking statements'' 
      within the meaning of the Private Securities Litigation Reform Act of 
      1995, as amended, including statements regarding the efficacy of 
      potential products, the timelines for bringing such products to market 
      and the availability of funding sources for continued development of 
      such products. Forward-looking statements are not historical 
      facts but are based on management's estimates, assumptions and 
      projections, and are subject to uncertainties, many of which are beyond 
      the control of PharmAthene. Actual results may differ materially 
      from those anticipated in any forward-looking statement. Factors 
      that may cause such differences include the risks that (a) potential 
      products that appear promising to PharmAthene or any of their 
      collaborators cannot be shown to be efficacious or safe in subsequent 
      preclinical or clinical trials, (b) PharmAthene or its collaborators 
      will not obtain appropriate or necessary governmental approvals to 
      market these or other potential products, (c) PharmAthene may not be 
      able to obtain anticipated funding for its development projects or other 
      needed funding, (d) PharmAthene may not be able to secure funding 
      from anticipated government contracts and grants, and (e) PharmAthene 
      may not be able to secure or enforce adequate legal protection, 
      including patent protection, for their products. The information 
      contained in this press release should be read in light of such risks. 
      The Company does not assume any obligation to update the information 
      contained in this press release.